gunnar

By joining forces with Meiwafosis, we aim to expand our commercial footprint and provide Japanese researchers with access to our innovative cell transfection technologies. This collaboration will make cell engineering more gentle and effective, empowering groundbreaking advancements in the field.

Stay tuned for more updates as we embark on this exciting journey together!

Join nearly 4,000 scientists from around the globe at ISSCR 2025 to take part in a 4-day program comprising the year’s most significant new advances in the field.

This award, which is awarded globally, recognizes spin-offs that translate original, high-quality scientific research into products and services that address market problems and have a positive impact on society. In the final, Trince eventually beat two American and one British opponent.

Trince received this award from the Nature jury for its groundbreaking research into photoporation, a new and safer method for introducing DNA and other molecules into cells. This new method can play a key role in the future of cell and gene therapy in the treatment of cancer and genetic diseases, and therefore has the potential to save many lives.

ASGCT’s annual meeting brings together more than 3,400 professionals including scientists, physicians, and patient advocates.

ISCT offers a unique collaborative environment that addresses three key areas of translation: Academia, Regulatory, and Commercialization. Through strong relationships with global regulatory agencies, academic institutions, and industry partners, ISCT drives the advancement of research into a standard of care.

Fotoporatie is een nieuwe en veilige methode om moleculen van buitenaf in cellen te plaatsen, met als doel die genetisch te wijzigen. Zo kunnen bijvoorbeeld immuuncellen, eens teruggebracht in de patiënt, beter ziektes zoals kanker bestrijden. Eos sprak met professor Kevin Braeckmans, hoofd van de onderzoeksgroep biofotonica aan de Universiteit Gent en bedenker van het innovatieve proces.

The event is for the leaders of pioneering ATMP companies and their most senior executives in charge of the latest tech and strategies that are driving the industry forward.

With 10 tracks of content, the agenda covers everything from manufacturing, supply chain & logistics, pricing & market access, to developments in key therapeutic areas; cell therapy, gene therapy, gene modified cell therapy, immunotherapy, and much more.

The scientific sessions will explore the development of new probes (organic, inorganic, nanoparticles, fluorescent proteins, hybrid materials), how to leverage their optical properties (spectra, quantum yield, lifetime, photostability, switching between dye states, etc…) and new instrumentations taking advantage of these new probes for life science.